| Literature DB >> 18523613 |
Abstract
Sexual assault occurs with alarming frequency in Canada. The prevalence of Posttraumatic Stress Disorder (PTSD) in assault survivors is drastically higher than the national prevalence of the disorder, which is a strong indication that the current therapies for sexual-assault-related PTSD are in need of improvement. Increasing knowledge and understanding of the pathologies associated with rape trauma in biological, psychological and sociological domains will help to develop more effective treatments for survivors. A dysregulation of the Hypothalamic-Pituitary-Adrenal (HPA) axis is observed in survivors of sexual assault and this may be a fundamental cause of the structural and functional abnormalities contributing to PTSD symptoms. Pharmacotherapies are available to treat PTSD; however, they are often inadequate or unwanted by the survivor. Psychological health is compromised following interpersonal trauma and many psychological therapies are available, but with varying efficacy. A person's cognitions have a dramatic effect on the onset, severity, and progress of PTSD following sexual assault. Sociological impacts of assault influence the development of PTSD through victim-blaming attitudes and the perpetuation of rape myths. Perceived positive regard and early social support is shown to be important to successful recovery. Education is vital in rape prevention and to foster a supportive environment for survivors. The biological, psychological and sociological impacts and treatments should not remain mutually exclusive. A better appreciation of the biopsychosocial repercussions of sexual assault will aid in developing a more holistic and individualized therapy to help alleviate the physical and emotional pain following the trauma of rape.Entities:
Keywords: pharmacotherapy; posttraumatic stress disorder; rape; sexual assault; trauma
Year: 2006 PMID: 18523613 PMCID: PMC2323517
Source DB: PubMed Journal: Mcgill J Med ISSN: 1201-026X
Figure 1The hypothalamic-pituitary-adrenal axis
The HPA axis is dysregulated in survivors of sexual assault. A reduced responsiveness to CRH is observed and the negative feedback by cortisol on the hypothalamus and pituitary is disturbed.
[Retrieved April 9th, 2006 from http://www.montana.edu/wwwai/imsd/alcohol/Vanessa/vwhpa_files/image003.jpg]
Summary of pharmacologic treatment options for PTSD
| Tricyclic antidepressants | Amitryptiline
| - 50% of treated patients had a final CGI-I |
| Monoamine Oxidase Inhibitors | Phenelzine
| - 45% decrease from baseline in IES score as compared to 5% for placebo
|
| Selective Serotonin Reuptake Inhibitors | Fluoxetine
| - 85% of treated patients showed improvement on a Global Rating Scale as compared to 62% of patients taking placebo
|
| 5-HT2 Antagonist | Nefazodone | - A decrease in PTSD severity on a Primary Assessment Scale in both combat veterans and civilians was observed |
| Anticonvulsants | Lamotrigine
| - 50% of patients in treatment group responded as compared to 25% for placebo group*
|
Clinical Global Impressions-Improvement Scale
Impact of Events Scale
Clinician Administered PTSD Scale
Davidson Trauma Scale
8-Item Treatment-Outcome PTSD Scale